The biotech sector, under the life sciences umbrella, exited 2023 with 41 bankruptcies. This was not surprising given the disparity between biotech’s high-capital requirements and rising interest rates set by the Fed. Despite these challenges, some of the best biotech stocks show promise and resilience in a volatile market environment.At the same time, smaller biotech deals became prevalent, accounting for $17 billion during 2023, per JP Morgan data. Another noticeable trend was the uptick in mergers and ac ...